Treatment of Meibomian Gland Dysfunction

Thermal Pulsation System for the Treatment of Meibomian Gland Dysfunction

NCT01683318•Singapore National Eye Centre

Summary

The current study aims to test the efficacy of treatment for a device that utilises a thermal pulsation system, which applies heat from the inner surface of the eyelids (Lipiflow) in patients suffering from meibomian gland dysfunction. Patients will be asked to undergo a one-time treatment with Lipiflow and the investigators will monitor them for changes in tear film and lipid composition, as well as changes in the anatomy of meibomian glands for over a study period of 12 weeks. Additionally, dry eye symptoms will be documented in form of questionnaires. The investigators hypothesize that the treatment will be effective in improving clinical signs and will relieve dry eye symptoms for the patient. If this method of managing Meibomian Gland Dysfunction (MGD) is found to be efficacious and safe, it will be made available to patients in Singapore.

Eligibility

Age

21 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Eyelids must present with blocked meibomian gland openings (plugs), at least 1 visible MG plug in the 4 eyelids, or discernable change in consistency of meibum (increased in viscosity or opacity) when MG expressed in upper or lower eyelids.
•2. At least one out of 8 questions on dry eye symptoms is answered with often or all the time.
•3. Eyes should not show any other ocular surface pathology which required more treatment than eye lubricant and conventional eyelid hygiene.

Exclusion Criteria

•1. Known history of thyroid disorders (diagnosed by physician).
•2. No ocular surgery within the previous 6 months and LASIK within the previous 1 year.
•3. Any intake of central nervous system and hormonal drugs within last 30 days and inability to withhold such drugs for at least 6 weeks.
•4. Active ocular infection or pterygium.
•5. Anticipated necessity to wear contact lens in the duration of the study.
•6. Living in the same household as another participant of the study.
•7. Any other specified reason as determined by clinical investigator, for example, the need to use any treatment or eyedrops not permitted by the study.

Locations (1)

Singapore National Eye Centre

Singapore, Singapore, Singapore

Key Dates

Start Date

September 1, 2012

Primary Completion Date

October 1, 2013

Last Updated

November 13, 2013

Enrollment

ACTUAL participants

Conditions

Meibomian Gland Dysfunction (MGD)

Interventions

Thermal Pulsation therapy

PROCEDURE

Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction

NCT07224529

Meibomian Gland Dysfunction (MGD)

View study

COMPLETEDPHASE2

An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)

NCT03972501

Meibomian Gland Dysfunction (MGD)Contact Lens Discomfort (CLD)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 13, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions